Want to see FBLG full AI Analyst Report?
Total Valuation
FibroBiologics, Inc. has a market cap or net worth of $9.59M. The enterprise value is $3.89.
Market Cap$9.59M
Enterprise Value$3.89
Share Statistics
FibroBiologics, Inc. has 6,658,193 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6,658,193
Owned by Insiders94.16%
Owned by Institutions2.42%
Financial Efficiency
FibroBiologics, Inc.’s return on equity (ROE) is -3.03 and return on invested capital (ROIC) is -194.36%.
Return on Equity (ROE)-3.03
Return on Assets (ROA)-1.94
Return on Invested Capital (ROIC)-194.36%
Return on Capital Employed (ROCE)-2.12
Revenue Per Employee0.00
Profits Per Employee-1.24M
Employee Count15
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of FibroBiologics, Inc. is ―. FibroBiologics, Inc.’s PEG ratio is -0.02.
PE Ratio―
PS Ratio0.00
PB Ratio1.63
Price to Fair Value1.63
Price to FCF-0.60
Price to Operating Cash Flow-0.61
PEG Ratio-0.02
Income Statement
In the last 12 months, FibroBiologics, Inc. had revenue of 0.00 and earned -18.65M in profits. Earnings per share was -8.35.
Revenue0.00
Gross Profit-832.00K
Operating Income-16.65M
Pretax Income-18.65M
Net Income-18.65M
EBITDA-17.61M
Earnings Per Share (EPS)-8.35
Cash Flow
In the last 12 months, operating cash flow was -14.79M and capital expenditures -6.00K, giving a free cash flow of -14.80M billion.
Operating Cash Flow-14.79M
Free Cash Flow-14.80M
Free Cash Flow per Share-2.22
Dividends & Yields
FibroBiologics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.89
52-Week Price Change-88.22%
50-Day Moving Average0.88
200-Day Moving Average3.52
Relative Strength Index (RSI)76.54
Average Volume (3m)978.93K
Important Dates
FibroBiologics, Inc. upcoming earnings date is Nov 17, 2026, After Close (Confirmed).
Last Earnings DateJul 31, 2026
Next Earnings DateNov 17, 2026
Ex-Dividend Date―
Financial Position
FibroBiologics, Inc. as a current ratio of 3.61, with Debt / Equity ratio of 31.54%
Current Ratio3.61
Quick Ratio3.61
Debt to Market Cap0.00
Net Debt to EBITDA0.14
Interest Coverage Ratio-81.61
Taxes
In the past 12 months, FibroBiologics, Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
FibroBiologics, Inc. EV to EBITDA ratio is -0.43, with an EV/FCF ratio of -0.45.
EV to Sales0.00
EV to EBITDA-0.43
EV to Free Cash Flow-0.45
EV to Operating Cash Flow-0.46
Balance Sheet
FibroBiologics, Inc. has $3.52M in cash and marketable securities with $1.46M in debt, giving a net cash position of $2.05M billion.
Cash & Marketable Securities$3.52M
Total Debt$1.46M
Net Cash$2.05M
Net Cash Per Share$0.31
Tangible Book Value Per Share$2.76
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for FibroBiologics, Inc. is $6.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$6.00
Price Target Upside745.07% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast22.10%